Antibiotic-associated dysbiosis disrupts gut microbiota balance, reducing microbial diversity and creating a niche for pathogenic organisms. This imbalance can impair epithelial barrier integrity, alter gene expression, and trigger local and systemic inflammation, ultimately contributing to chronic and immune-related disorders.^[1] While antibiotics remain essential, their misuse increases the risk of antibiotic-associated diarrhea (AAD) and resistance. Probiotics play a crucial role in restoring microbial balance, and Saccharomyces boulardii CNCM I-745 offers distinct advantages. As a yeast probiotic, it remains effective even during antibiotic use, stabilizes gut microbiota, reduces AAD risk, and helps prevent Clostridioides difficile infection. Its robust action supports gut barrier function, reduces inflammation, and improves overall gastrointestinal health outcomes.^[2][3]